213 related articles for article (PubMed ID: 33543516)
1. Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants.
Hempenius M; Groenwold RHH; Souverein PC; de Boer A; Klungel OH; Gardarsdottir H
Br J Clin Pharmacol; 2021 Sep; 87(9):3508-3517. PubMed ID: 33543516
[TBL] [Abstract][Full Text] [Related]
2. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
[TBL] [Abstract][Full Text] [Related]
3. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease.
Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
Br J Clin Pharmacol; 2022 Mar; 88(3):994-1009. PubMed ID: 34409636
[TBL] [Abstract][Full Text] [Related]
4. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation.
Douros A; Renoux C; Yin H; Filion KB; Suissa S; Azoulay L
Am J Med; 2019 Feb; 132(2):191-199.e12. PubMed ID: 30691551
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions.
Kirchmayer U; Narduzzi S; Mayer F; Tuccori M; Leoni O; Belleudi V; Di Martino M; Lallo A; Addis A; Davoli M
Recenti Prog Med; 2019 Apr; 110(4):195-202. PubMed ID: 31066365
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
[TBL] [Abstract][Full Text] [Related]
8. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis.
Hum J; Shatzel JJ; Jou JH; Deloughery TG
Eur J Haematol; 2017 Apr; 98(4):393-397. PubMed ID: 28009449
[TBL] [Abstract][Full Text] [Related]
10. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
[TBL] [Abstract][Full Text] [Related]
11. The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation.
van den Dries CJ; van Doorn S; Souverein P; Pajouheshnia R; Moons KGM; Hoes AW; Geersing GJ; van den Ham HA
TH Open; 2020 Oct; 4(4):e417-e426. PubMed ID: 33376941
[No Abstract] [Full Text] [Related]
12. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
13. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.
Olsen AS; McGettigan P; Gerds TA; Fosbøl EL; Olesen JB; Sindet-Pedersen C; Staerk L; Lock Hansen M; Pallisgaard JL; Køber L; Torp-Pedersen C; Gislason GH; Lamberts M
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):292-300. PubMed ID: 31742339
[TBL] [Abstract][Full Text] [Related]
14. Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.
Law SWY; Lau WCY; Wong ICK; Lip GYH; Mok MT; Siu CW; Chan EW
J Am Coll Cardiol; 2018 Jul; 72(3):271-282. PubMed ID: 30012320
[TBL] [Abstract][Full Text] [Related]
15. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study.
Paschke LM; Klimke K; Altiner A; von Stillfried D; Schulz M
BMC Med; 2020 Aug; 18(1):254. PubMed ID: 32847578
[TBL] [Abstract][Full Text] [Related]
16. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
[TBL] [Abstract][Full Text] [Related]
17. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis.
Rujirachun P; Charoenngam N; Wattanachayakul P; Winijkul A; Owattanapanich W; Ungprasert P
Acta Cardiol; 2020 Dec; 75(8):724-731. PubMed ID: 31558097
[No Abstract] [Full Text] [Related]
19. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
[TBL] [Abstract][Full Text] [Related]
20. Trends in anticoagulant prescribing: a review of local policies in English primary care.
Ho KH; van Hove M; Leng G
BMC Health Serv Res; 2020 Apr; 20(1):279. PubMed ID: 32245380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]